-
The report on the procurement of magnetic therapy equipment in the first quarter of 2022 is released, and this province is the most active
Time of Update: 2022-08-12
Data source: JOINCHAIN ® Zhongcheng Digital Science Observation from the model, in the first quarter of 2022, the magnetic therapy equipment of Osaifu model MS 080 ranked first, of which the total bid amount and quantity were 2.
-
Following national policies closely, Jingxiaofu has deployed online medical insurance pilots to promote the integration of online and offline development.
Time of Update: 2022-08-11
01 Keep up with national policies01 Follow national policies closely "Guiding Opinions on Medical Insurance Payment" , the opinion points out: Doing a good job in "Internet +" medical service medical
-
The "little wormwood" that costs a few yuan during the Dragon Boat Festival has become a characteristic "big industry"
Time of Update: 2022-08-11
According to reports, with the strong support of relevant government departments and With the help of e-commerce platforms such as Pinduoduo, local wormwood enterprises are more confident in brand building and future development.
-
Jiangxi: Guotan drugs are divided into three categories, 68 varieties are not included in the dual channel
Time of Update: 2022-08-11
Jiangxi clearly defines the classified management of Guotan drugs, among which the negotiated drugs with longer use cycle and higher treatment course cost are included in the "dual-channel" category A drug management; high clinical value, urgent need for patients, low substitution, specific drug users (major and extra large).
-
In the first quarter, the net profit exceeded 14 billion pharmaceutical stocks!
Time of Update: 2022-08-11
It is worth noting that due to the impact of the new crown epidemic in 2020, only 4 companies with revenue exceeding 10 billion yuan in the first quarter ; 63 losses are amazing!
-
Steady Medical's 750 million yuan holding Ping An Medical Equipment enters the new track of injection and puncture category
Time of Update: 2022-08-10
Acquisition and capital increase of Hunan Ping An Medical Equipment Enter the new track of injection and puncture categoryEnter the new track of injection and puncture category Enter the new track of injection and puncture category Hunan Ping An Medical Equipment is mainly engaged in the research and development, production and sales of injection and puncture medical consumables (including syringes, infusion sets, blood collection tubes, blood collection needles, indwelling needles and other products).
-
The constant over-review of generic drugs is further promoting the industry reshuffle!
Time of Update: 2022-08-10
After review, the above-mentioned drugs passed the consistency evaluation of the quality and efficacy of chemical generic drugs It is understood that there are many pharmaceutical companies that have over-reviewed drugs recently.
-
The neurotherapy market has a broad space for development, and leading pharmaceutical companies are increasing their plans for AD/PD
Time of Update: 2022-08-10
. In addition, in order to further alleviate the burden of Alzheimer's disease patients in China, pharmaceutical companies are accelerating the development of new drugs and providing patients with more choices.
-
This track has become a new blue ocean market for medicine, and local pharmaceutical companies are actively deploying
Time of Update: 2022-08-10
[Pharmaceutical Network Market Analysis] On May 18, Zhongsheng Pharmaceutical announced that its subsidiary Chia Tai Tianqing signed an agreement with Symhogen A/S, a wholly-owned subsidiary of Servi
-
Affected by rising costs, OTC may welcome a small price increase again
Time of Update: 2022-08-10
[Pharmaceutical Network Market Analysis] Recently, China Resources Sanjiu mentioned in its institutional survey, "The price of OTC products is relatively market-oriented, and the company has certain
-
The competition in the diabetes drug market has intensified, and a large number of pharmaceutical companies are gathering hot targets
Time of Update: 2022-08-10
and weight loss medications At present, in addition to the three domestic innovative diabetes drugs, Benaglutide Injection, Macrogolloxenatide Injection, and Siglitatide Sodium Tablets, the domestic pharmaceutical companies have accelerated their research and development.
-
The implementation of the national standard for traditional Chinese medicine formula granules, related companies are concerned by institutions and investors
Time of Update: 2022-08-10
In this regard, the company stated that at present, the company's traditional Chinese medicine formula granules have completed the filing of 60 national standard varieties, and the original Guizhou provincial standard varieties are currently on sale .
-
The "going overseas" of innovative drugs has suffered setbacks one after another, how should local pharmaceutical companies solve the "going to sea"
Time of Update: 2022-08-10
From the current Judging from the situation of companies going overseas, domestic biopharmaceutical companies are not going smoothly, and there is still a long way to go for the international development of domestic drugs Previously, the listing process of Chi-Med's surufatinib in the United States was also pressed on the pause button; in addition, Innovent and Coherus also jointly announced the termination of the cooperation on the bevacizumab biosimilar IBI-305.
-
The export of traditional Chinese medicine will continue to accelerate, and traditional Chinese medicine enterprises will usher in a period of development opportunities
Time of Update: 2022-08-10
For example, Guangxi proposed that during the "14th Five-Year Plan" period, it will strive to create a national export base of traditional Chinese medicine services, explore the development of "Internet + traditional Chinese medicine trade", build a medicinal material trade processing zone by relying on ports, expand and strengthen the professional market for traditional Chinese medicinal materials, and create China-ASEAN trade channel of traditional Chinese medicine and traditional medicine .
-
The first launch meeting of "Kehuang Capsules in the Treatment of Non-Alcoholic Fatty Liver Disease" was held in Zhengzhou
Time of Update: 2022-08-10
On May 15, the launch meeting of "Kehuang Capsule Intervention of Non-Alcoholic Fatty Liver Disease (Damp Heat Intrinsic Syndrome) Multi-center, Randomized Double-blind, Placebo Parallel Control Clinical Trial" was successfully held in Zhengzhou, Henan .
-
In 2022, the concentration of blood products industry will continue to increase
Time of Update: 2022-08-10
. However, it is worth noting that because blood products have both resource attributes and policy barrier resource attributes, and in recent years, the country's newly approved plasma stations have become increasingly strict, and the scale effect of blood products has become more and more obvious, and the industry concentration is also increasing.
-
my country's drug smart supervision will enter a new stage, and drug quality and safety will be more guaranteed
Time of Update: 2022-08-10
[Pharmaceutical Network Market Analysis] On the 11th, the State Food and Drug Administration issued the "14th Five-Year Plan for Drug Regulatory Network Security and Informatization Construction" . T
-
Inventory of new drugs approved for listing in China, the United States and Europe in February
Time of Update: 2022-05-27
Neimatevir tablets/ritonavir tablets (trade name Paxlovid) are a combination of two antiviral drugs, nematevir and ritonavir, developed by Pfizer for the treatment of adults with progressive Patients with mild to moderate novel coronavirus pneumonia (COVID-19) with high risk factors for severe disease, such as patients with high risk factors for severe disease such as advanced age, chronic kidney disease , diabetes, cardiovascular disease, and chronic lung disease .
-
WHO: Coronavirus death rates rise to highest in some countries
Time of Update: 2022-05-26
WHO Director-General Tedros Adhanom Ghebreyesus said that affected by the epidemic in Asia and Europe, the number of new coronary pneumonia cases continued to increase globally, and the death rate of new coronary pneumonia in some countries rose to the highest level .
-
The Anxiety and Opportunity Behind Evolving Innovative Enterprises to Biopharma
Time of Update: 2022-05-25
In the first half of the domestic PD-1 field, the battle for indications and medical insurance has come to an end, and the market pattern has quietly changed: Junshi Bio’s PD-1 has not changed the trend even if it handed over the promotion rights to AZ in non-core cities in China; In contrast, Kangfang Bio's piamprilumab sold a total of 212 million yuan in more than 3 months .
